Device Trial Radar · NCT07685834
Evaluation of Facial and Neck Skin Laxity With SofWave Treatment in Adults Initiating Tirzepatide for Weight Loss
Last checked: Nov 19, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Feb 27, 2026
Primary completion
Mar 1, 2027
Study completion Mar 1, 2027
Sponsor
- Lead sponsor
- Sofwave Medical LTDNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 6, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- Female only, from 30 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Open-label, randomized double-arm prospective, single-center, self-controlled clinical study.
Conditions
- Lax Skin
Interventions
SUPERBDevice
The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues. Pure Impact is an EMS module. This module is wirelessly connected to and controlled by the SofWave console. It functions independently from the existing ultrasound module. Pure Impact generates electrical impulses, which are delivered through electrodes on the skin in direct proximity to the muscles to be stimulated.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Improvement in the appearance of lax skinTime frame: 20 WEEKS POST LAST TREATMENT
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dr.Jean Carruthers Cosmetic Surgery
Vancouver, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.